We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

Promotion of drugs and devices at international conferences held in Canada
  • Torys LLP
  • Canada
  • February 3 2009

As a neighbor, Canada is often selected as a venue for international conferences of U.S. drug and device manufacturers


Canada's approach to functional foods
  • Torys LLP
  • Canada
  • April 21 2010

Today’s diet- and health-conscious environment has led to a proliferation of functional food marketing claims that advertise the specific health-enhancing characteristics of a food product


Ontario court confirms generic drug manufacturers not entitled to unjust enrichment
  • Torys LLP
  • Canada
  • January 22 2013

On January 15, 2013, the Ontario Superior Court of Justice (Ontario Court) granted a motion for partial summary judgment in Apotex Inc. v. Abbott


Canada’s Federal Court of Appeal limits damages available to delayed generics
  • Torys LLP
  • Canada
  • June 8 2009

On June 4, 2009, in Merck Frosst Canada Inc. v. Apotex, Inc., the Federal Court of Appeal released an important decision limiting the range of damages available in actions under section 8 of the Patented Medicines (Notice of Compliance) Regulations


Canada proposes amendments to adverse drug reaction reporting
  • Torys LLP
  • Canada
  • June 18 2009

On June 13, 2009, proposed regulations amending the Food and Drug Regulations with respect to adverse drug reaction reporting (Proposed Regulations) were published in the Canada Gazette


Canada’s regulation of subsequent entry biologics
  • Torys LLP
  • Canada
  • April 6 2009

Health Canada has released a revised version of the draft guidance document "Information and Submission Requirements for Subsequent Entry Biologics."


Canadian privacy commissioners release guidance on workplace H1N1 privacy
  • Torys LLP
  • Canada
  • November 18 2009

On October 29, 2009 the Office of the Privacy Commissioner of Canada (OPC), together with the Privacy Commissioners’ offices of Alberta and British Columbia, published a guidance document titled "Privacy in the Time of a Pandemic: Guidance for Organizations."


Data protection in Canada: Court of Appeal confirms narrow approach
  • Torys LLP
  • Canada
  • January 30 2013

On January 18, 2013, the Federal Court of Appeal (FCA) released its decision in Takeda Canada Inc. v. The Minister of Health and Attorney General of


Innovative drugs sold under the special access programme can receive data protection in Canada
  • Torys LLP
  • Canada
  • May 18 2011

To benefit from data protection in Canada, a drug must meet the definition of "innovative drug" under the Food and Drug Regulations


Court affirms Health Canada’s broad discretion in review of drug submissions
  • Torys LLP
  • Canada
  • April 13 2010

In a recent decision of the Federal Court in Hospira Healthcare Corporation v. Canada (Attorney General) the Court affirmed that Health Canada has broad discretion in interpreting the Food and Drug Regulations to determine the content of an application for the marketing approval of a drug